Galectin Therapeutics Inc Unit Cons of 2 shs + 1 Wt(NASDAQ : GALTU)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Loading GALTU News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.32%||67.61||1.0%||$592.31m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.20%||368.39||2.1%||$317.11m|
|KITE||Kite Pharma, Inc.||-1.38%||75.33||18.8%||$207.24m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.13%||120.23||1.6%||$206.05m|
|ESPR||Esperion Therapeutics, Inc.||0.43%||39.18||18.7%||$165.22m|
|AUPH||Aurinia Pharmaceuticals Inc.||-0.35%||8.50||6.3%||$148.24m|
|CLVS||Clovis Oncology, Inc.||3.86%||69.77||17.5%||$146.91m|
|VRTX||Vertex Pharmaceuticals Incorporated||0.22%||90.24||2.2%||$135.26m|
|GBT||Global Blood Therapeutics Inc||1.84%||38.70||11.9%||$106.43m|
Galectin Therapeutics, Inc. operates as a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease and cancer. Its drug candidates are based on the method of targeting galectin proteins, which are key mediators of biologic and pathologic function and its focus is on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The company was founded by James C. Czirr and Anatole A. Kltyosov on July 10, 2000 and is headquartered in Norcross, GA.